Results 1 to 10 of about 8,460 (141)
Molecules, 2021 Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, one of the main characteristics of which is the abnormal accumulation of amyloid peptide (Aβ) in the brain. Whereas β-secretase supports Aβ formation along the amyloidogenic processing
Arpita Dey +6 more
doaj +1 more source
Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease
Frontiers in Molecular Neuroscience, 2020 Alzheimer’s disease (AD) is the most common type of senile dementia, characterized by neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were devoted to the interference with the production and accumulation of amyloid ...
Jing Zhao +7 more
doaj +1 more source
Computer-assisted evaluation of plant-derived β-secretase inhibitors in Alzheimer’s disease
Egyptian Journal of Medical Human Genetics, 2021 Background Alzheimer’s disease (AD) is a progressive neurodegenerative age-related dementia that results in memory loss of elderly people. Many hypotheses have been formally articulated till now to decipher the pathogenesis of this disease.
Md. Asad Ullah +6 more
doaj +1 more source
Frontiers in Molecular Neuroscience, 2018 The competitive ectodomain shedding of amyloid-β precursor protein (APP) by α-secretase and β-secretase, and the subsequent regulated intramembrane proteolysis by γ-secretase are the key processes in amyloid-β peptides (Aβ) generation.
Xin Wang, Gang Pei, Gang Pei
doaj +1 more source
The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease [PDF]
, 2015 Alzheimer's disease (AD) is the most common form of dementia in the elderly and its prevalence is set to increase rapidly in coming decades. However, there are as yet no available drugs that can halt or even stabilize disease progression. One of the main
Baillie, George S. +3 more
core +1 more source
Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein
Cell Reports, 2016 Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD). AD is characterized by toxic β-amyloid (Aβ) peptides produced by β- and γ-secretase-mediated cleavage of the amyloid precursor protein (APP).
Saoussen Ben Halima +10 more
doaj +1 more source
Neuronal human BACE1 knock-in induces systemic diabetes in mice [PDF]
, 2016 Acknowledgements The authors thank S. Tammireddy (Diabetes and Cardiovascular Science, University of the Highlands and Islands, Inverness, UK) for technical support with the lipidomics component. Funding We would like to thank R.
Dekeryte, Ruta +12 more
core +4 more sources
Shrimp (Pandalopsis dispar) waste hydrolysate as a source of novel β–secretase inhibitors
Fisheries and Aquatic Sciences, 2016 In this study, purified peptides from shrimp waste hydrolysates (SWHs) were examined for their inhibitory effects against β–secretase. During consecutive purification using a Sephadex G–25 column chromatography and high performance liquid chromatography ...
Eunice C. Y. Li-Chan +2 more
doaj +1 more source
Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice [PDF]
, 2012 Insulin resistance and impaired glucose homoeostasis are important indicators of Type 2 diabetes and are early risk factors of AD (Alzheimer's disease).
Alex J. Harper +62 more
core +4 more sources
The resveratrol trimer miyabenol C inhibits β-secretase activity and β-amyloid generation.
PLoS ONE, 2015 Accumulation and deposition of amyloid-β peptide (Aβ) in the brain is a primary cause of the pathogenesis of Alzheimer's disease (AD). Aβ is generated from amyloid-β precursor protein (APP) through sequential cleavages first by β-secretase and then by γ ...
Jin Hu +9 more
doaj +1 more source